logo
Pluristem_logo
We have entered a collaboration agreement with one of the world’s leading manufacturers of specialty biologic APIs for liver and gastroenterological diseases. We believe that proof of concept with this agreement and APIs will open opportunities for us to serve additional API manufacturers in the rapidly growing, multi-billion-dollar biologics market

Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in ...

Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued the following update to shareholders from Chief Executive Officer and President Yaky Yanay announcing that it had signed its second technology collaboration agreement centered on Pluri’s 3D cell expansion platform and providing some financial status updates

By Pluri Inc.
Published - Sep 29, 2022, 07:06 AM ET
Last Updated - Jul 12, 2024, 04:19 AM EDT
  • Newcompanystrategywill reduce cash burn by approximately30%, with$56M in cashonconsolidatedbalance sheet
  • Leading European manufacturer of active pharmaceutical ingredients (APIs) to usePluri’s3D cell expansion technology,which aims torevolutionizethe production of biologics by enabling cost-effective, sustainable, and cruelty-free ingredients
  • Agreement marksPluri’ssecond tech collaboration following joint venture withTnuvaGroup to develop cultivated food products
    • Article Source
    Quick Links
    Categories
    Our Offices
    • 10kInfo, Inc.
      13555 SE 36th St
      Bellevue, WA 98006
    • 10kInfo Data Solutions, Pvt Ltd.
      Claywork Create
      11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
      Bengaluru, Karnataka 560076
    4.2 12182024